A new study from Karolinska Institutet and Karolinska University Hospital shows that only a small proportion of patients who were examined for cognitive illness at the specialized memory reception at Karolinska Hospital in Solna had biomarker profiles typical of Alzheimer's disease and could be considered as potential candidates for new disease-modifying treatments. against amyloid.
This study was done in collaboration between Karolinska Institutet and Janssen Pharmaceutica NV (part of Janssen Pharmaceutical Companies of Johnson & Johnson), and was published online in the journal Neurology, the medical journal of the American Academy of Neurology.
Biomarkers that reflect typical changes in brain pathology in Alzheimer's disease are an important support in the diagnosis, as well as finding which patient group is suitable for which new disease-modifying treatment, when such drugs become available in the market. At present, however, there is only limited data on the proportion of patients in regular clinics and memory clinics (ie who are not participants in research studies) who have Alzheimer's-type biomarkers and who could thus be the right patient group for these new drugs.
Large patient base at the Solna memorial reception
In this study, the research team led by Professor Miia Kivipelto, MD PhD, has examined biomarker profiles in a well-characterized patient group at the memorial reception at Karolinska University Hospital in Solna. The clinical investigation process at the newly started clinic (which opened in 2018) has given rise to a large amount of well-documented information. The memory reception receives patients with memory problems from primary care in the reception area as well as younger patients under 70 years from the entire Stockholm region. The investigation process follows a "fast track model" where a majority of all investigations are done within a week. Most patients undergo lumbar puncture for spinal cord fluid collection, magnetic camera examination of the brain, and most neuropsychological tests. These survey results are then compiled into a diagnosis. All patients are also asked for permission to participate in the hospital's research database and biobank (GEDOC).